CDTX - H.C. Wainwright analyst lowers price target on Cidara Therapeutics
H.C. Wainwright Analyst Ed Arce lowered the price target on Cidara Therapeutics (NASDAQ:CDTX) to $6 from $7.50. The Buy rating on CDTX shares was kept. The biotechnology company had reported Q1 GAAP EPS of -$0.27 and revenue of $7.11M (+195.0% Y/Y).
For further details see:
H.C. Wainwright analyst lowers price target on Cidara Therapeutics